Item 2.01. Completion of Acquisition or Disposition of Assets.
As previously noted in Item 1.01, on December 20, 2018, the Company entered into the License Agreement with CSH. Pursuant to the License Agreement, the Company is being granted an exclusive license by CSH for the United States of America, Canada, Mexico, all countries in the Caribbean Sea and all other countries north of the Panama/Columbia border (including the entire nation of Panama), with respect to certain patents and intellectual property and associated technical information for the production of phytocannabinoids for use in medical treatments and in exchange for 210,000,000 shares of common stock of the Company.
